AN INVESTIGATION OF THE PREVALENCE AND SIGNIFICANCE OF GASTRIC PARIETAL-CELL AUTOANTIBODY IN RHEUMATOID ARTHRITIS

BY

ERNEST M. ARMSTRONG

Fourth Year Medical Student, Centre for Rheumatic Diseases, Glasgow

Anti-gamma globulin autoantibodies or rheumatoid factors have been detected in the serum of approximately 70-80 per cent. of patients with rheumatoid arthritis (RA) (Ziff, 1957; Glynn and Holborow, 1960; Singer, 1961; Vaughan and Butler 1962), and antinuclear autoantibodies or factors have been detected in approximately 30 per cent. of patients with the disease (Alexander, Bremmer, and Duthie, 1960; Hall, Bardawil, Bayles, Mednis, and Galins, 1960; Beck, 1963; Ward, Johnson, and Holborow, 1964; Pitkeathly and Taylor, 1967). In addition to these non-organ-specific autoantibodies, some workers (Anderson, Goudie, Gray, and Buchanan, 1961; Buchanan, Crooks, Alexander, Koutras, Wayne, and Gray, 1961; Becker, Ferguson, and McConahey, 1963; Becker, Titus, Woolner, and Ferguson, 1963; Kornstad and Kornstad, 1964) but not all (Hijmans, Doniach, Roitt, and Holborow, 1961; Masi, Hartmann, Hahn, Abbey, and Shulman, 1965; Mulhern, Masi, and Shulman, 1966) have noted an increased prevalence of organ-specific thyroid autoantibodies and chronic thyroiditis in patients with RA. The position regarding the prevalence of gastric parietal-cell autoantibodies in RA is not clear, although Roitt, Doniach, and Shapland (1965) have noted that the “incidence is only slightly raised above that of controls”.

The first purpose of this study was to define the prevalence of gastric parietal-cell autoantibody in patients with RA, and to compare this with the prevalence found in patients with other forms of arthritis, such as osteo-arthritis, Reiter’s disease, psoriatic arthritis, ankylosing spondylitis, and gout. The second purpose of the study was to determine whether the gastric parietal-cell autoantibody found in some patients with RA resulted from a non-organ-specific autoantibody which stained the cytoplasm of gastric parietal cells, or whether it was organ-specific as in pernicious anaemia (Irvine, Davies, Delamore, and Wynn Williams, 1962; Markson and Moore, 1962; Taylor, Roitt, Doniach, Couchman, and Shapland, 1962; Irvine 1965) and iron deficiency anaemia (Markson and Moore, 1962; Dagg, Goldberg, Anderson, Beck, and Gray, 1964) and associated with chronic atrophic gastritis.

Material and Methods

Patients Studied

Gastric parietal-cell autoantibody was studied in the sera of 325 patients with “probable”, “definite”, and “classical” RA as defined by the American Rheumatism Association criteria (Ropes, Bennett, Cobb, Jacob, and Jessar, 1959) and in the sera of 231 patients with osteo-arthritis, fifteen with Reiter’s disease, fourteen with psoriatic arthritis, twelve with gout, and three with ankylosing spondylitis. The age and sex distribution of these patients is shown in Table I (overleaf).

Immunofluorescence

The gastric parietal-cell autoantibody was studied by an immunofluorescent sandwich technique described by Adams, Glen, Kennedy, Mackenzie, Morrow, Anderson, Gray, and Middleton (1964). The serum was tested undiluted against 5μ cryostat sections of the body of fresh human stomach obtained at operation for peptic ulcer. Sections were randomly dispersed within large batches of routine slides in the immunopathology laboratory and read by the author and by another two experienced, independent observers. Only strongly-positive staining was considered indicative of the presence of the autoantibody.

Specificity of Autoantibody

26 patients with RA were selected for further study. Twelve had positive tests for gastric parietal-cell autoantibody, and the specificity of their serum was checked in a dilution of 1 in 16 using 5μ cryostat sections of rat kidney and in a dilution of 1 in 4 using 5μ cryostat sections of fresh human thyroid gland obtained at thyroidectomy, as recommended by Roitt, Doniach, and Shapland (1965). The remaining fourteen had negative
tests for gastric parietal-cell autoantibody and were used as controls.

The clinical and laboratory data are summarized in Table II, and details of drug therapy in these two groups are shown in Table III (opposite).

Both groups were well matched for age and sex, duration of arthritis, articular index (co-operating Clinics Committee of the American Rheumatism Association, 1965), presence of subcutaneous nodules, positive sheep cell agglutination tests (SCAT) (Heller, Jacobson, Kolodny, and Kammerer, 1954), antinuclear factor (ANF) tests (Beck, 1961), serum globulin levels, and haemoglobin concentrations. The control patients with negative tests for gastric parietal-cell autoantibodies had significantly lower serum albumin levels ($t = 3.175$; $P < 0.01$) and significantly higher erythrocyte sedimentation rates ($t = 2.205$; $P < 0.05$). The two groups were comparable with regard to drug therapy (Table III). although significantly more of the patients with gastric parietal-cell autoantibody in their serum had received phenylbutazone therapy in the past ($\chi^2 = 6.527$; $P < 0.01$).

### Gastric Function Tests

Augmented histamine test meals (Kay, 1953) were carried out by the following technique.

After an overnight fast, a No. 16 gauge radio-opaque tube (Neoplex, Rayx, Porges, France) was passed *per nasam* into the stomach. The patient was placed comfortably on the left side and the tube manoeuvred while hand suction was applied until the position of maximum drainage was ascertained. The tube was then fixed in position and continuous suction of 5-10 mm. Hg was applied using a continuous suction pump.* The position of the tube was confirmed radiologically in two patients in the test group (Cases 2 and 12) and two controls (Cases 3 and 4). The tubes were checked regularly during the test to ensure patency.

After the gastric tube had been passed the stomach contents were aspirated for 30 minutes and discarded. The aspirate over the next 30 minutes was collected and represented *basal acid secretion.*


### Table I

**Prevalence of Gastric Parietal Cell Autoantibody in Patients with Rheumatoid Arthritis and Various Other Arthritides**

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Sex</th>
<th>Age (yrs)</th>
<th>Number of Patients</th>
<th>Positive Immunofluorescent Tests for Gastric Parietal-Cell Autoantibody</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean</td>
<td>Range</td>
<td>Number</td>
</tr>
<tr>
<td>Rheumatoid Arthritis . . . . .</td>
<td>Female</td>
<td>49.4</td>
<td>6-81</td>
<td>246</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>42.7</td>
<td>18-73</td>
<td>79</td>
</tr>
<tr>
<td>Osteo-arthritis . . . . . . .</td>
<td>Female</td>
<td>60.2</td>
<td>23-74</td>
<td>141</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>51.6</td>
<td>42-64</td>
<td>90</td>
</tr>
<tr>
<td>Reiter’s Disease . . . . . .</td>
<td>Male</td>
<td>29.3</td>
<td>17-55</td>
<td>15</td>
</tr>
<tr>
<td>Psoriatic Arthritis . . . . .</td>
<td>Female</td>
<td>43.6</td>
<td>20-65</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>38.0</td>
<td>29-47</td>
<td>2</td>
</tr>
<tr>
<td>Gout . . . . . . . . . . .</td>
<td>Female</td>
<td>59.0</td>
<td>59-59</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>53.3</td>
<td>36-83</td>
<td>10</td>
</tr>
<tr>
<td>Ankylosing Spondylitis . . .</td>
<td>Male</td>
<td>46.3</td>
<td>38-45</td>
<td>3</td>
</tr>
</tbody>
</table>

### Table II

**Clinical and Laboratory Data in Twelve Patients with Rheumatoid Arthritis**

<table>
<thead>
<tr>
<th>Tests for Gastric Parietal-Cell Autoantibody</th>
<th>Total Number of Patients</th>
<th>Age (yrs)</th>
<th>Sex</th>
<th>Duration of Arthritis (yrs)</th>
<th>Articular Index*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>12</td>
<td>57.08 ± 7.75 (12)</td>
<td>1</td>
<td>8.0 ± 5.1 (12)</td>
<td>17.0 ± 13.6 (7)</td>
</tr>
<tr>
<td>Negative</td>
<td>14</td>
<td>50.57 ± 8.99 (14)</td>
<td>2</td>
<td>7.8 ± 5.7 (14)</td>
<td>27.6 ± 16.3 (10)</td>
</tr>
<tr>
<td>Tests of Significance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Mepyramine malleate† 100 mg. was then administered intramuscularly, and 0·04 mg./kg. body weight of histamine acid phosphate B.P.‡ was given by subcutaneous injection 30 minutes later. Gastric aspiration was continued during this time and for a further 15 minutes after administration of the histamine: this aspirate was discarded. The aspirate collected during the subsequent 30 minutes represented the maximum acid secretion (Kay, 1953).

The pH of both gastric juice specimens was measured using a glass electrode, and 10 ml. aliquots of the aspirates were titrated against standard N/10 NaOH using Tophifer's reagent and Phenol red as indicators, thus giving a measure of free and total acidity. The free acid is hydrochloric acid and the total acid includes the contribution by acid mucoprotein residues and organic acids. The maximal free acid secretion has been shown to correlate with total parietal-cell mass both in human beings (Card and Marks, 1960) and in dogs (Marks, Komarov, and Shay, 1960).

Statistical Methods

Data were analysed either by a standard Student's "t" test or by a χ² analysis. Where small numbers were involved in the χ² analysis, Yates's correction for continuity was employed.

Results

Prevalence of Gastric Parietal-cell Autoantibody in Arthritic Patients

Table I shows that the prevalence of positive tests for gastric parietal-cell autoantibody in female patients with "probable", "definite", and "classical" RA (16·2 per cent.) is similar to that in female patients with osteo-arthritis (17 per cent.). Five of the 79 male patients with RA had positive tests for gastric parietal-cell autoantibody, whereas none of ninety male patients with osteo-arthritis had positive tests; these differences are, however, not significant. There was a low prevalence of gastric parietal-cell autoantibodies in patients with other arthritides.

Specificity of Gastric Parietal-cell Autoantibody in Patients with RA

The results of the immunofluorescent tests for non-specific autoantibody reacting with rat kidney tubules and human thyroid epithelium in twelve patients with RA and positive tests for gastric parietal-cell autoantibody are as follows:

None of the twelve sera showed fluorescence with rat kidney tubules. A positive test with human thyroid epithelium was seen in one serum and a weak positive reaction in a further two. In each of these three cases, however, the staining was of the specific type, being finely granular and being confined to the epithelial cells. Thus no evidence was found for any non-specific autoantibody in any of these twelve patients.

Correlation of Presence of Gastric Parietal-cell Autoantibody with Gastric Secretory Function in Patients with RA

The results of the augmented histamine test meals in the twelve patients with RA who had
positive tests for gastric parietal-cell autoantibody and the fourteen controls are shown in Table IV. Eleven of the twelve positive patients had no detectable free or total acid in the basal specimen, whereas only six of the fourteen controls had achlorhydria in the basal specimen. These differences are, however, not significant. The differences between the two groups are more marked in the post-histamine specimens. If histamine-fast hypochlorhydria is defined as $<$ 2·0 mEq/hr of maximal free acid secretion in the post-histamine hour, then it can be seen that nine of the twelve positive patients and only two of the fourteen controls had hypochlorhydria. These differences are significant ($x^2 = 7·429; P < 0·05$). No correlation was found between any current or past drug therapy, in particular oral analgesics and the results of the augmented histamine test, but the numbers involved in the two groups, are, of course, too small to allow any concrete statistical analysis of this point.

<table>
<thead>
<tr>
<th>Immunofluorescent test for gastric parietal-cell autoantibody</th>
<th>Positive</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Patients</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>Basal Achlorhydria</td>
<td>11</td>
<td>6</td>
</tr>
<tr>
<td>Post-Histamine Hypochlorhydria ($\leq$ 2·0 mEq/hr)</td>
<td>9</td>
<td>2*</td>
</tr>
</tbody>
</table>

*$x^2 = 7·429; P < 0·05$

**Discussion**

Although there is some evidence for an increased prevalence of organ-specific thyroid autoantibodies and chronic thyroiditis in patients with RA, the present study has shown no evidence of an increased prevalence of gastric parietal-cell autoantibodies (Table I). These observations are consistent with those of Roitt and others (1965), who also found no significant increase in prevalence of gastric parietal-cell autoantibody. It is of interest, however, that an increase prevalence of gastric parietal-cell autoantibodies has been observed in Glasgow in female patients with Sjögren's syndrome (Goudie and Buchanan, 1967), although no increased prevalence was noted in the serum of patients with Sjögren's syndrome diagnosed by the same criteria at the National Institutes of Health, Bethesda, Maryland, U.S.A., when tested in the same laboratory in Glasgow (Anderson, Beck, Bloch, Buchanan, and Bunim, 1965).

Gastric parietal-cell autoantibody is found in the serum of over 80 per cent. of patients with pernicious anaemia (Irvine and others, 1962; Taylor and others, 1962; Bernhardt, Burkett, Fields, and Killian, 1965; De Boer, Nairn, and Maxwell, 1965) and is also commonly found in the serum of patients suffering from a variety of other autoimmune diseases, such as autoimmune thyroiditis (Doniach, Roitt, and Taylor, 1963; Irvine, 1966), thyrotoxicosis (Doniach and others, 1963), and iron deficiency anaemia (Markson and Moore, 1962; Dagg and others, 1964), as well as in miscellaneous conditions such as diabetes mellitus (Moore and Neilson, 1963), and in a proportion of apparently healthy people. Where the autoantibody is present in the absence of pernicious anaemia, gastric mucosal biopsy invariably reveals chronic atrophic gastritis associated with varying degrees of impairment of gastric secretion following maximal histamine stimulation (Irvine, 1965; Adams and others, 1964; Irvine, Davies, Teitelbaum, Delamore, and Wynn Williams, 1965; Coghill, Doniach, Roitt, Mollin, and Wynn Williams 1965; Williams, Scott, Beck, and Blair, 1966).

In twelve positive patients who had no non-organ specific autoantibody demonstrable by testing against rat kidney and human thyroid (Roitt and others, 1965), a significant impairment of gastric acid secretion as detected by the augmented histamine test meal (Kay, 1953) was demonstrated as compared with fourteen controls matched for age and sex. (The fact that the control patients were in a more active phase of the disease as shown by hypoalbuminaemia and raised erythrocyte sedimentation rate was not considered to have influenced the results of the augmented histamine test meals.) This presumably reflects chronic atrophic gastritis in these patients with gastric parietal-cell autoantibodies, since there is evidence that the degree of hypochlorhydria is related to the viable parietal-cell mass and to the extent of chronic atrophic gastritis (Card and Marks, 1960; Marks and others, 1960; Irvine, 1966). It was not felt justified to submit these patients to the inconvenience and potential hazard of gastric mucosal biopsy to prove this point completely.

The oral analgesic and corticosteroid drugs used in the treatment of RA are known to influence gastric function (Kirsner and Ford, 1955; Mauer, 1955; Weiss, Pitman, and Graham, 1961; Scott, Porter, Lewis, and Dixon, 1961; Ballabio, Ciria, Girardi, Caruso, and Colombo, 1963; Rothermich, 1966), but in the present study there was no correlation between the past or present administration of any one drug and the results of the augmented histamine test meals, although the numbers involved preclude any statistical analysis of this point.
It is concluded that there is no increased prevalence of gastric parietal-cell autoantibodies in RA patients, but that when such autoantibodies are found they are organ-specific and are related to chronic atrophic gastritis with impairment of gastric acid secretory function. Further studies would be of interest to determine the relationship of gastric parietal-cell autoantibodies to latent pernicious anaemia in patients suffering from RA.

**Summary**

The prevalence of gastric parietal-cell autoantibody was studied in patients with rheumatoid arthritis, using an immunofluorescent sandwich technique, and was found to be similar to that in osteo-arthritis controls matched for age and sex. The prevalence in various other forms of arthritis was also found to be low.

Twelve patients with rheumatoid arthritis and positive tests for gastric parietal-cell autoantibody were selected for further study. The gastric parietal-cell autoantibody was shown in these patients to be organ-specific by exclusion of sera containing non-specific autoantibody demonstrable by testing against rat kidney and human thyroid gland. Augmented histamine test meals in these patients showed significant impairment of gastric acid secretion as compared with fourteen age- and sex-matched controls with rheumatoid arthritis and negative tests for gastric parietal-cell autoantibody. No correlation was found between gastric secretory function and past or present drug therapy.

It is concluded that there is no increased prevalence of gastric parietal-cell autoantibodies in rheumatoid arthritis, but that when this autoantibody is present it is organ-specific and reflects chronic atrophic gastritis with histamine-fast hypochlorhydria.

I gratefully acknowledge the receipt of a research grant from the Arthritis and Rheumatism Council without which this work would not have been possible. My thanks are due to Dr. R. B. Goudie and Dr. R. N. M. McSween of the University Department of Pathology, Western Infirmary, Glasgow, for guidance in the immunological aspects of this study, and to Dr. J. A. Boyle, Dr. W. W. Buchanan, and Dr. M. K. Jasani of the University Department of Medicine and the Centre for Rheumatic Diseases, Baird Street, Glasgow, for advice and encouragement in the clinical aspects. I must also mention the invaluable assistance afforded to me at all times by the staff of the Regional Immunopathology Laboratory and by the Sisters and nursing staff of the Centre for Rheumatic Diseases.

**REFERENCES**


GASTRIC PARIETAL-CELL AUTOANTIBODY


Une étude de la fréquence et de la signification des autoanticorps anti-muqueuse gastrique dans l'arthrite rhumatismale

RÉSUMÉ

On étudia la fréquence avec laquelle on trouvait des autoanticorps anti-muqueuse gastrique chez des malades atteints d'arthrite rhumatismale en utilisant le procédé d'immunofluorescence "en sandwich" et on trouva des résultats comparables à ceux des témoin ostéoarthrosiques compté tenu de l'âge et du sexe. De même, cette fréquence fut basse dans d'autres formes d'arthrite.

On retint pour une étude ultérieure douze malades atteints d'arthrite rhumatismale chez lesquels on avait trouvé des autoanticorps anti-muqueuse gastrique. Chez ces malades on démontra que les autoanticorps anti-muqueuse gastrique étaient spécifiques de l'organe en éliminant les sérum contenant des autoanticorps non spécifiques, identifiés par leur action sur le rein de rat et sur la thyroïde humaine. L'épreuve à l'histamine montra chez ces malades une inhibition significative de la sécrétion gastrique acide par rapport à 14 témoin d'âge et de sexe comparables ayant une arthrite rhumatismale mais pas d'autoanticorps anti-muqueuse gastrique. On n'a pas trouvé de corrélation entre la fonction sécrétoire gastrique et l'absorption passée ou présente de médicaments.

On conclut que la fréquence d'autoanticorps anti-muqueuse gastrique n'est pas augmentée dans l'arthrite rhumatismale, mais quand ces autoanticorps existent, ils sont spécifiques de l'organe et présentent une manifestation d'une gastrite atrophique chronique avec hypochlorhydrie résistante à l'histamine.

Una investigación de la frecuencia y del significado de los autoanticuerpos contra la mucosa gástrica en la artritis reumatoide

SUMARIO

Se estudió la incidencia del autoanticuerpo contra la mucosa gástrica en enfermos con artritis reumatoide, empleando el procedimiento de inmunofluorescencia "en sandwich"; los resultados hallados fueron similares a los obtenidos en testigos osteoartrósicos, con tener cuenta de la edad y el sexo. La incidencia en varias otras formas de artritis fue también baja.

Se escogieron para una investigación ulterior doce enfermos con artritis reumatoide y con autoanticuerpos contra la mucosa gástrica comprobados. Se demostró en estos enfermos que los autoanticuerpos contra la mucosa gástrica fueron específicos del órgano por exclusión de los sueros con autoanticuerpos no específicos, identificados por reacciones contra el riñon de rata y la glándula tiroides humana. Pruebas de la histamina evidenciaron en estos enfermos una inhibición significativa de la secreción gástrica acida en comparación con 14 testigos de edad y de sexo comparables, afectos de artritis reumatoide sin autoanticuerpo contra la mucosa gástrica. No se halló correlación alguna entre la función secretoria gástrica y la terapéutica medicamentosa pasada o presente.

Se concluye que la incidencia de autoanticuerpos contra la mucosa gástrica no se ve aumentada en la artritis reumatoide, pero los autoanticuerpos que existen son específicos del órgano y reflejan una gastritis atófica crónica con hipoclorhidria resistente a la histamina.
An investigation of the prevalence and significance of gastric parietal-cell autoantibody in rheumatoid arthritis.

E M Armstrong

Ann Rheum Dis 1967 26: 499-505
doi: 10.1136/ard.26.6.499

Updated information and services can be found at:
http://ard.bmj.com/content/26/6/499.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/